Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01261754 · ClinicalTrials.gov registry record · Phase 1
A Study of 99mTc-MIP-1404 and 99mTc-MIP-1405 in Patients With Metastatic Prostate Adenocarcinoma and Healthy Volunteers
A Phase 1 study, sponsored by Molecular Insight Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT01261754 is a Phase 1 study that has completed, run by Molecular Insight Pharmaceuticals. The registered enrollment target is 16 participants.
The verdict
NCT01261754, a Phase 1 study, has completed, sponsored by Molecular Insight Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This is a single-blind, randomized, cross-over design. Patients with metastatic prostate adenocarcinoma; newly diagnosed, high-risk patients with prostate adenocarcinoma; and healthy subjects will be administered a single intravenous dose of each of the study drugs 99mTc MIP 1404 and 99mTc MIP 1405 administered approximately 14 to 21 days apart.
Interventions
- RADIATION 99mTc MIP 1404
- RADIATION 99mTc MIP 1405
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2010-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01261754
The ClinicalTrials.gov registry entry for NCT01261754 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Molecular Insight Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 99mTc MIP 1404 is the first listed.
NCT01261754 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01261754 about?
NCT01261754 is a clinical study titled "A Study of 99mTc-MIP-1404 and 99mTc-MIP-1405 in Patients With Metastatic Prostate Adenocarcinoma and Healthy Volunteers". This is a single-blind, randomized, cross-over design. Patients with metastatic prostate adenocarcinoma; newly diagnosed, high-risk patients with prostate adenocarcinoma; and healthy subjects will be administered a single intravenous dose of each of the study drugs 99mTc MIP 1404 and 99mTc MIP 1405 ...
What is the current status of trial NCT01261754?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2010-12.
What interventions are being tested in trial NCT01261754?
The interventions under investigation include: 99mTc MIP 1404 (RADIATION), 99mTc MIP 1405 (RADIATION).
Who is sponsoring clinical trial NCT01261754?
This trial is sponsored by Molecular Insight Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.